Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro

Emmanual Unni, Dimpy Koul, Wai Kwan Alfred Yung, Raghu Sinha

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Introduction: Se-methylselenocysteine (MSC), a naturally occurring selenium compound, is a promising chemopreventive agent against in vivo and in vitro models of carcinogen-induced mouse and rat mammary tumorigenesis. We have demonstrated previously that MSC induces apoptosis after a cell growth arrest in S phase in a mouse mammary epithelial tumor cell model (TM6 cells) in vitro. The present study was designed to examine the involvement of the phosphatidylinositol 3-kinase (PI3-K) pathway in TM6 tumor model in vitro after treatment with MSC. Methods: Synchronized TM6 cells treated with MSC and collected at different time points were examined for PI3-K activity and Akt phosphorylation along with phosphorylations of Raf, MAP kinase/ERK kinase (MEK), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein kinase (MAPK). The growth inhibition was determined with a [3H]thymidine incorporation assay. Immunoblotting and a kinase assay were used to examine the molecules of the survival pathway. Results: PI3-K activity was inhibited by MSC followed by dephosphorylation of Akt. The phosphorylation of p38 MAPK was also downregulated after these cells were treated with MSC. In parallel experiments MSC inhibited the Raf-MEK-ERK signaling pathway. Conclusion: These studies suggest that MSC blocks multiple signaling pathways in mouse mammary tumor cells. MSC inhibits cell growth by inhibiting the activity of PI3-K and its downstream effector molecules in mouse mammary tumor cells in vitro.

Original languageEnglish (US)
Article numberR699
JournalBreast Cancer Research
Volume7
Issue number5
DOIs
StatePublished - Jul 6 2005

Fingerprint

Phosphatidylinositol 3-Kinase
Epithelial Cells
Breast Neoplasms
Phosphotransferases
raf Kinases
Phosphorylation
p38 Mitogen-Activated Protein Kinases
Growth
Selenium Compounds
In Vitro Techniques
selenomethylselenocysteine
Mitogen-Activated Protein Kinase Kinases
S Phase
Immunoblotting
Carcinogens
Thymidine
Carcinogenesis
Breast
Down-Regulation
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{fe15e9acdf2e4d07afc81afd3dbe4b77,
title = "Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro",
abstract = "Introduction: Se-methylselenocysteine (MSC), a naturally occurring selenium compound, is a promising chemopreventive agent against in vivo and in vitro models of carcinogen-induced mouse and rat mammary tumorigenesis. We have demonstrated previously that MSC induces apoptosis after a cell growth arrest in S phase in a mouse mammary epithelial tumor cell model (TM6 cells) in vitro. The present study was designed to examine the involvement of the phosphatidylinositol 3-kinase (PI3-K) pathway in TM6 tumor model in vitro after treatment with MSC. Methods: Synchronized TM6 cells treated with MSC and collected at different time points were examined for PI3-K activity and Akt phosphorylation along with phosphorylations of Raf, MAP kinase/ERK kinase (MEK), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein kinase (MAPK). The growth inhibition was determined with a [3H]thymidine incorporation assay. Immunoblotting and a kinase assay were used to examine the molecules of the survival pathway. Results: PI3-K activity was inhibited by MSC followed by dephosphorylation of Akt. The phosphorylation of p38 MAPK was also downregulated after these cells were treated with MSC. In parallel experiments MSC inhibited the Raf-MEK-ERK signaling pathway. Conclusion: These studies suggest that MSC blocks multiple signaling pathways in mouse mammary tumor cells. MSC inhibits cell growth by inhibiting the activity of PI3-K and its downstream effector molecules in mouse mammary tumor cells in vitro.",
author = "Emmanual Unni and Dimpy Koul and Yung, {Wai Kwan Alfred} and Raghu Sinha",
year = "2005",
month = "7",
day = "6",
doi = "10.1186/bcr1276",
language = "English (US)",
volume = "7",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "5",

}

Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. / Unni, Emmanual; Koul, Dimpy; Yung, Wai Kwan Alfred; Sinha, Raghu.

In: Breast Cancer Research, Vol. 7, No. 5, R699, 06.07.2005.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro

AU - Unni, Emmanual

AU - Koul, Dimpy

AU - Yung, Wai Kwan Alfred

AU - Sinha, Raghu

PY - 2005/7/6

Y1 - 2005/7/6

N2 - Introduction: Se-methylselenocysteine (MSC), a naturally occurring selenium compound, is a promising chemopreventive agent against in vivo and in vitro models of carcinogen-induced mouse and rat mammary tumorigenesis. We have demonstrated previously that MSC induces apoptosis after a cell growth arrest in S phase in a mouse mammary epithelial tumor cell model (TM6 cells) in vitro. The present study was designed to examine the involvement of the phosphatidylinositol 3-kinase (PI3-K) pathway in TM6 tumor model in vitro after treatment with MSC. Methods: Synchronized TM6 cells treated with MSC and collected at different time points were examined for PI3-K activity and Akt phosphorylation along with phosphorylations of Raf, MAP kinase/ERK kinase (MEK), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein kinase (MAPK). The growth inhibition was determined with a [3H]thymidine incorporation assay. Immunoblotting and a kinase assay were used to examine the molecules of the survival pathway. Results: PI3-K activity was inhibited by MSC followed by dephosphorylation of Akt. The phosphorylation of p38 MAPK was also downregulated after these cells were treated with MSC. In parallel experiments MSC inhibited the Raf-MEK-ERK signaling pathway. Conclusion: These studies suggest that MSC blocks multiple signaling pathways in mouse mammary tumor cells. MSC inhibits cell growth by inhibiting the activity of PI3-K and its downstream effector molecules in mouse mammary tumor cells in vitro.

AB - Introduction: Se-methylselenocysteine (MSC), a naturally occurring selenium compound, is a promising chemopreventive agent against in vivo and in vitro models of carcinogen-induced mouse and rat mammary tumorigenesis. We have demonstrated previously that MSC induces apoptosis after a cell growth arrest in S phase in a mouse mammary epithelial tumor cell model (TM6 cells) in vitro. The present study was designed to examine the involvement of the phosphatidylinositol 3-kinase (PI3-K) pathway in TM6 tumor model in vitro after treatment with MSC. Methods: Synchronized TM6 cells treated with MSC and collected at different time points were examined for PI3-K activity and Akt phosphorylation along with phosphorylations of Raf, MAP kinase/ERK kinase (MEK), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein kinase (MAPK). The growth inhibition was determined with a [3H]thymidine incorporation assay. Immunoblotting and a kinase assay were used to examine the molecules of the survival pathway. Results: PI3-K activity was inhibited by MSC followed by dephosphorylation of Akt. The phosphorylation of p38 MAPK was also downregulated after these cells were treated with MSC. In parallel experiments MSC inhibited the Raf-MEK-ERK signaling pathway. Conclusion: These studies suggest that MSC blocks multiple signaling pathways in mouse mammary tumor cells. MSC inhibits cell growth by inhibiting the activity of PI3-K and its downstream effector molecules in mouse mammary tumor cells in vitro.

UR - http://www.scopus.com/inward/record.url?scp=33644874428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644874428&partnerID=8YFLogxK

U2 - 10.1186/bcr1276

DO - 10.1186/bcr1276

M3 - Article

C2 - 16168115

AN - SCOPUS:33644874428

VL - 7

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 5

M1 - R699

ER -